Sabby Management’s COSCIENS Biopharma Inc. Common Stock CSCI Stock Holding History

Sabby Management’s Portfolio CSCI Stock Details CSCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-2,442	Closed	-$214K	–	204
2021 Q2	$214K	Sell	2,442 -3,542	-59%	-$337K	0.03%	131
2021 Q1	$682K	Buy	+5,984	New	+$663K	0.13%	93
2020 Q1	–	Sell	-1,020	Closed	-$93K	–	108
2019 Q4	$93K	Buy	1,020 +299	+41%	+$27.9K	0.03%	61
2019 Q3	$74K	Buy	721 +593	+463%	+$128K	0.04%	77
2019 Q2	$38K	Buy	+128	New	+$45.1K	0.05%	80
2017 Q3	–	Sell	-673	Closed	-$67K	–	213
2017 Q2	$67K	Buy	+673	New	+$107K	﹤0.01%	200
2017 Q1	–	Sell	-4,006	Closed	-$1.18M	–	324
2016 Q4	$1.44M	Buy	4,006 +3,336	+498%	+$1.24M	0.08%	128
2016 Q3	$230K	Sell	670 -1,988	-75%	-$697K	0.01%	269
2016 Q2	$867K	Sell	2,658 -2,267	-46%	-$816K	0.05%	171
2016 Q1	$1.64M	Sell	4,925 -416	-8%	-$137K	0.08%	120
2015 Q4	$2.39M	Buy	+5,341	New	+$3.35M	0.13%	108

Other funds holding CSCI

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Natixis Paris, France $28B AUM 26.79% 1-Year Est. Return

EDRH

Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Sabby Management's CSCI Position: Q3 2021 in Review

Sabby Management sold out of COSCIENS Biopharma Inc. Common Stock (CSCI) in Q3 2021, closing a stake of 2,442 shares — an estimated $214K sold.

Sabby Management first reported a position in CSCI in Q4 2015 and held it in 11 quarters. The position peaked at $2.39M in Q4 2015. 31 funds tracked by Wall St. Rank hold CSCI as of Q3 2021.

Sabby Management reported no remaining COSCIENS Biopharma Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
Sabby Management sold 2,442 COSCIENS Biopharma Inc. Common Stock shares in Q3 2021, an estimated $214K.
Sabby Management first reported a position in COSCIENS Biopharma Inc. Common Stock in Q4 2015 and held it in 11 quarters.
Sabby Management's COSCIENS Biopharma Inc. Common Stock position peaked at $2.39M in Q4 2015.
31 funds tracked by Wall St. Rank held COSCIENS Biopharma Inc. Common Stock as of Q3 2021.

Based on Sabby Management's 13F filing for Q3 2021, filed 15 Nov 2021.